

## Results of General Meeting

**PERTH, Australia, 24 October 2025:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix<sup>®</sup> AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, advises that the resolutions considered at today's General Meeting of Shareholders were all passed on a poll.

In accordance with listing rule 3.13.2 and section 251AA of the Corporations Act the details of the votes cast on each of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](http://www.linkedin.com/company/artrya)

### For more information:

#### Corporate Enquiries

**John Konstantopoulos**  
Co-Founder and Chief Executive Officer  
Tel: +61 8 6478 7816  
Email: [contact@artrya.com](mailto:contact@artrya.com)

#### Investor & Media Enquiries

**David Allen or John Granger**  
Hawkesbury Partners  
Tel: +61 499 100 038 or +61 410 577 155  
Email: [investors@artrya.com](mailto:investors@artrya.com)

## Results of meeting

Name of entity

Artrya Limited

ABN/ACN/ARSN/ARBN

624 005 741

Date of meeting

24 October 2025

Resolutions voted on at the meeting					If decided by poll <sup>5</sup>					Proxies received <sup>6</sup>			
Resolution		Result <sup>2</sup>	Voting method <sup>3</sup>	If s250U applies <sup>4</sup>	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion <sup>9</sup>
No <sup>1</sup>	Short description				Number	% <sup>7</sup>	Number	% <sup>8</sup>	Number	Number	Number	Number	Number
1	Ratification of Tranche 1 Placement Shares	Passed	Poll	N/a	25,639,323	97.77%	585,174	2.23%	25,930,241	25,247,101	585,174	25,930,241	285,610
2	Ratification of Tranche 1 Placement Shares	Passed	Poll	N/a	25,639,323	97.77%	585,174	2.23%	25,930,241	25,247,101	585,174	25,930,941	285,610
3	Approval to Issue Tranche 2 Placement Shares	Passed	Poll	N/a	25,629,323	97.73%	595,174	2.27%	25,930,241	25,237,101	595,174	25,930,941	285,610